Effects of captopril on mortality and morbidity rates in patients with left ventricular dysfunction following myocardial infarction: Results of survival and ventricular hypertrophic studies

M. A. Pfeffer, J. Braumwald, L. A. Moye, L. Basta, E. J. Brown, T. E. Caddi, B. R. Davis, E. M. Geltman, Steven Goldman, G. S. Fleiker, M. Klein, G. A. Lamas, M. Paker, J. Pulo, J. L. Rulo, J. Razerford, J. H. Wertheimer, S. M. Hokins

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Left ventricular dilation and dysfunction after myocardial infarction are major predictors of death. In experimental and clinical studies, long-term therapy with captopril, an angiotensin-converting enzyme inhibitor, decreased ventricular dilation and rearrangement. This study was undertaken to examine whether captopril may reduce morbidity and mortality in patients with left ventricular dysfunction following myocardial infarction. On days 3 to 16 after myocardial infarction. 2231 patients with <40% ejection fraction, but without signs of obvious, heart failure or symptoms of myocardial ischemia were studied in a double-blind study,of them 1116 took placebo and 1115 had captopril. The follow-up averaged 42 months. The mortality due to any causes was significantly lower in the captopril group (228 deaths or 20% than in the placebo group (275 deaths or 25%). The decrease in the risk was 19 percent (95 percent confidence interval, 3 to 32 percent; p=0.019). The incidence of fatal and grave nonfatal cardiovascular events significantly decreased in captopril-treated patients. The risk decrease was 21 percent (95 percent confidence interval, 5 to 35 percent; p=0.014) for cardiovascular mortality; 37 percent (95 percent confidence interval, 20 to 50 percent; p<0.001) for the development of severe heart failure; 22 percent (95 percent confidence, 4 to 37 percent, p=0.019) for congestive heart failure requiring hospitalization; 25 percent (95 percent confidence interval, 5 to 40 percent; p=0.015) for recurrent myocardial infarction. Thus, long-term captopril use in patients with asymptomatic left ventricular dysfunction following prior myocardial infarction resulted in survival improvement and decreased morbidity and mortality due to severe cardiovascular events. There were positive results both in patients treated with thrombolytics, aspirin or beta-blockers and in those untreated with the above drugs. This suggests that the use of captopril additionally improved the therapeutic outcomes in patients with prior myocardial infection.

Original languageEnglish (US)
JournalKardiologiia
Volume33
Issue number12
StatePublished - 1993
Externally publishedYes

Fingerprint

Captopril
Left Ventricular Dysfunction
Myocardial Infarction
Morbidity
Survival
Mortality
Confidence Intervals
Heart Failure
Dilatation
Placebos
Double-Blind Method
Angiotensin-Converting Enzyme Inhibitors
Aspirin
Myocardial Ischemia
Hospitalization
Incidence
Therapeutics
Infection
Pharmaceutical Preparations

Keywords

  • Captopril
  • Left ventricular dysfunction
  • Morbidity
  • Mortality
  • Myocardial infarction
  • Treatment

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Effects of captopril on mortality and morbidity rates in patients with left ventricular dysfunction following myocardial infarction : Results of survival and ventricular hypertrophic studies. / Pfeffer, M. A.; Braumwald, J.; Moye, L. A.; Basta, L.; Brown, E. J.; Caddi, T. E.; Davis, B. R.; Geltman, E. M.; Goldman, Steven; Fleiker, G. S.; Klein, M.; Lamas, G. A.; Paker, M.; Pulo, J.; Rulo, J. L.; Razerford, J.; Wertheimer, J. H.; Hokins, S. M.

In: Kardiologiia, Vol. 33, No. 12, 1993.

Research output: Contribution to journalArticle

Pfeffer, MA, Braumwald, J, Moye, LA, Basta, L, Brown, EJ, Caddi, TE, Davis, BR, Geltman, EM, Goldman, S, Fleiker, GS, Klein, M, Lamas, GA, Paker, M, Pulo, J, Rulo, JL, Razerford, J, Wertheimer, JH & Hokins, SM 1993, 'Effects of captopril on mortality and morbidity rates in patients with left ventricular dysfunction following myocardial infarction: Results of survival and ventricular hypertrophic studies', Kardiologiia, vol. 33, no. 12.
Pfeffer, M. A. ; Braumwald, J. ; Moye, L. A. ; Basta, L. ; Brown, E. J. ; Caddi, T. E. ; Davis, B. R. ; Geltman, E. M. ; Goldman, Steven ; Fleiker, G. S. ; Klein, M. ; Lamas, G. A. ; Paker, M. ; Pulo, J. ; Rulo, J. L. ; Razerford, J. ; Wertheimer, J. H. ; Hokins, S. M. / Effects of captopril on mortality and morbidity rates in patients with left ventricular dysfunction following myocardial infarction : Results of survival and ventricular hypertrophic studies. In: Kardiologiia. 1993 ; Vol. 33, No. 12.
@article{0e0dfb6e93454bebb7663f995090553c,
title = "Effects of captopril on mortality and morbidity rates in patients with left ventricular dysfunction following myocardial infarction: Results of survival and ventricular hypertrophic studies",
abstract = "Left ventricular dilation and dysfunction after myocardial infarction are major predictors of death. In experimental and clinical studies, long-term therapy with captopril, an angiotensin-converting enzyme inhibitor, decreased ventricular dilation and rearrangement. This study was undertaken to examine whether captopril may reduce morbidity and mortality in patients with left ventricular dysfunction following myocardial infarction. On days 3 to 16 after myocardial infarction. 2231 patients with <40{\%} ejection fraction, but without signs of obvious, heart failure or symptoms of myocardial ischemia were studied in a double-blind study,of them 1116 took placebo and 1115 had captopril. The follow-up averaged 42 months. The mortality due to any causes was significantly lower in the captopril group (228 deaths or 20{\%} than in the placebo group (275 deaths or 25{\%}). The decrease in the risk was 19 percent (95 percent confidence interval, 3 to 32 percent; p=0.019). The incidence of fatal and grave nonfatal cardiovascular events significantly decreased in captopril-treated patients. The risk decrease was 21 percent (95 percent confidence interval, 5 to 35 percent; p=0.014) for cardiovascular mortality; 37 percent (95 percent confidence interval, 20 to 50 percent; p<0.001) for the development of severe heart failure; 22 percent (95 percent confidence, 4 to 37 percent, p=0.019) for congestive heart failure requiring hospitalization; 25 percent (95 percent confidence interval, 5 to 40 percent; p=0.015) for recurrent myocardial infarction. Thus, long-term captopril use in patients with asymptomatic left ventricular dysfunction following prior myocardial infarction resulted in survival improvement and decreased morbidity and mortality due to severe cardiovascular events. There were positive results both in patients treated with thrombolytics, aspirin or beta-blockers and in those untreated with the above drugs. This suggests that the use of captopril additionally improved the therapeutic outcomes in patients with prior myocardial infection.",
keywords = "Captopril, Left ventricular dysfunction, Morbidity, Mortality, Myocardial infarction, Treatment",
author = "Pfeffer, {M. A.} and J. Braumwald and Moye, {L. A.} and L. Basta and Brown, {E. J.} and Caddi, {T. E.} and Davis, {B. R.} and Geltman, {E. M.} and Steven Goldman and Fleiker, {G. S.} and M. Klein and Lamas, {G. A.} and M. Paker and J. Pulo and Rulo, {J. L.} and J. Razerford and Wertheimer, {J. H.} and Hokins, {S. M.}",
year = "1993",
language = "English (US)",
volume = "33",
journal = "Kardiologiya",
issn = "0022-9040",
publisher = "Media Sfera",
number = "12",

}

TY - JOUR

T1 - Effects of captopril on mortality and morbidity rates in patients with left ventricular dysfunction following myocardial infarction

T2 - Results of survival and ventricular hypertrophic studies

AU - Pfeffer, M. A.

AU - Braumwald, J.

AU - Moye, L. A.

AU - Basta, L.

AU - Brown, E. J.

AU - Caddi, T. E.

AU - Davis, B. R.

AU - Geltman, E. M.

AU - Goldman, Steven

AU - Fleiker, G. S.

AU - Klein, M.

AU - Lamas, G. A.

AU - Paker, M.

AU - Pulo, J.

AU - Rulo, J. L.

AU - Razerford, J.

AU - Wertheimer, J. H.

AU - Hokins, S. M.

PY - 1993

Y1 - 1993

N2 - Left ventricular dilation and dysfunction after myocardial infarction are major predictors of death. In experimental and clinical studies, long-term therapy with captopril, an angiotensin-converting enzyme inhibitor, decreased ventricular dilation and rearrangement. This study was undertaken to examine whether captopril may reduce morbidity and mortality in patients with left ventricular dysfunction following myocardial infarction. On days 3 to 16 after myocardial infarction. 2231 patients with <40% ejection fraction, but without signs of obvious, heart failure or symptoms of myocardial ischemia were studied in a double-blind study,of them 1116 took placebo and 1115 had captopril. The follow-up averaged 42 months. The mortality due to any causes was significantly lower in the captopril group (228 deaths or 20% than in the placebo group (275 deaths or 25%). The decrease in the risk was 19 percent (95 percent confidence interval, 3 to 32 percent; p=0.019). The incidence of fatal and grave nonfatal cardiovascular events significantly decreased in captopril-treated patients. The risk decrease was 21 percent (95 percent confidence interval, 5 to 35 percent; p=0.014) for cardiovascular mortality; 37 percent (95 percent confidence interval, 20 to 50 percent; p<0.001) for the development of severe heart failure; 22 percent (95 percent confidence, 4 to 37 percent, p=0.019) for congestive heart failure requiring hospitalization; 25 percent (95 percent confidence interval, 5 to 40 percent; p=0.015) for recurrent myocardial infarction. Thus, long-term captopril use in patients with asymptomatic left ventricular dysfunction following prior myocardial infarction resulted in survival improvement and decreased morbidity and mortality due to severe cardiovascular events. There were positive results both in patients treated with thrombolytics, aspirin or beta-blockers and in those untreated with the above drugs. This suggests that the use of captopril additionally improved the therapeutic outcomes in patients with prior myocardial infection.

AB - Left ventricular dilation and dysfunction after myocardial infarction are major predictors of death. In experimental and clinical studies, long-term therapy with captopril, an angiotensin-converting enzyme inhibitor, decreased ventricular dilation and rearrangement. This study was undertaken to examine whether captopril may reduce morbidity and mortality in patients with left ventricular dysfunction following myocardial infarction. On days 3 to 16 after myocardial infarction. 2231 patients with <40% ejection fraction, but without signs of obvious, heart failure or symptoms of myocardial ischemia were studied in a double-blind study,of them 1116 took placebo and 1115 had captopril. The follow-up averaged 42 months. The mortality due to any causes was significantly lower in the captopril group (228 deaths or 20% than in the placebo group (275 deaths or 25%). The decrease in the risk was 19 percent (95 percent confidence interval, 3 to 32 percent; p=0.019). The incidence of fatal and grave nonfatal cardiovascular events significantly decreased in captopril-treated patients. The risk decrease was 21 percent (95 percent confidence interval, 5 to 35 percent; p=0.014) for cardiovascular mortality; 37 percent (95 percent confidence interval, 20 to 50 percent; p<0.001) for the development of severe heart failure; 22 percent (95 percent confidence, 4 to 37 percent, p=0.019) for congestive heart failure requiring hospitalization; 25 percent (95 percent confidence interval, 5 to 40 percent; p=0.015) for recurrent myocardial infarction. Thus, long-term captopril use in patients with asymptomatic left ventricular dysfunction following prior myocardial infarction resulted in survival improvement and decreased morbidity and mortality due to severe cardiovascular events. There were positive results both in patients treated with thrombolytics, aspirin or beta-blockers and in those untreated with the above drugs. This suggests that the use of captopril additionally improved the therapeutic outcomes in patients with prior myocardial infection.

KW - Captopril

KW - Left ventricular dysfunction

KW - Morbidity

KW - Mortality

KW - Myocardial infarction

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0027886339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027886339&partnerID=8YFLogxK

M3 - Article

C2 - 7910865

AN - SCOPUS:0027886339

VL - 33

JO - Kardiologiya

JF - Kardiologiya

SN - 0022-9040

IS - 12

ER -